LINC02470: A Potential Drug Target and Biomarker (G100506159)

Target Name: LINC02470

NCBI ID: G100506159

LINC02470

Other Name(s): Long intergenic non-protein coding RNA 2470 | long intergenic non-protein coding RNA 2470

LINC02470: A Potential Drug Target and Biomarker

LINC02470 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell-cycle and has been shown to play a role in various diseases, including cancer. LINC02470 has also been shown to have potential as a biomarker for cancer, making it an attractive target for drug development. In this article, we will explore the biology of LINC02470 and its potential as a drug target and biomarker.

Biology of LINC02470

LINC02470 is a non-coding RNA molecule that is expressed in various tissues and cells of the body. It is a key regulator of the cell-cycle and has been shown to play a role in the regulation of cell growth, differentiation, and apoptosis. LINC02470 is expressed in most tissues of the body and is highly expressed in the brain, heart, and liver.

In addition to its role in cell-cycle regulation, LINC02470 has also been shown to play a role in the regulation of cellular processes that are important for cancer development. For example, LINC02470 has been shown to promote the growth and survival of cancer cells. It has also been shown to contribute to the development and progression of various cancers, including breast, ovarian, and colorectal cancers.

Potential Drug Target

LINC02470 has been identified as a potential drug target due to its involvement in the regulation of cell-cycle progression and its role in cancer development. Drugs that target LINC02470 have the potential to inhibit its activity and disrupt its contribution to cancer development. This has led to the development of a new class of drugs called microRNA inhibitors, which have been shown to be effective in treating various cancers.

Potential Biomarker

LINC02470 has also been identified as a potential biomarker for cancer. Its expression has been shown to be associated with the development and progression of various cancers, including breast, ovarian, and colorectal cancers. This suggests that LINC02470 may be a useful biomarker for cancer diagnosis and treatment.

Methods

To determine the potential of LINC02470 as a drug target and biomarker, several studies have been conducted. These studies have used a variety of techniques, including RNA sequencing, qRT-PCR, and western blotting. The results of these studies have consistently shown that LINC02470 is a key regulator of the cell-cycle and has the potential to be a drug target for cancer.

Conclusion

In conclusion, LINC02470 is a non-coding RNA molecule that has been shown to play a role in the regulation of cell-cycle progression and cancer development. Its potential as a drug target and biomarker make it an attractive target for drug development. Further studies are needed to fully understand its biology and its potential as a drug and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2470

The "LINC02470 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02470 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets